BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bayer HealthCare (BAY) Enters into Distribution Agreement to Expand Markets for the Medrad™ Intego™ PET Infusion System


3/5/2013 10:50:40 AM

LEVERKUSEN, Germany and TARRYTOWN, N.Y., March 5, 2013 /PRNewswire/ -- Bayer HealthCare is expanding its global distribution network for the Medrad Intego PET Infusion System through a new distribution agreement with Comecer, SPA, a world leader in protection technologies in nuclear medicine. Through this agreement, Bayer and Comecer are providing customers with an integrated nuclear medicine solution combining the clinical administration capabilities of Intego with the Comecer's protection technologies for PET/CT[1] centers around the world.

According to Doug Descalzi, Bayer HealthCare's Sr. Director of Molecular Imaging Devices, this distribution agreement capitalizes on the strength of both companies. "This arrangement creates an end-to-end solution for customers, from isotope production to radiopharmaceutical infusion. We're pleased to be working with Comecer to not only provide greater patient access to Intego but also to provide comprehensive product solutions to nuclear medicine suites around the world."

Intego is a worldwide market leader in PET/CT, and the only FDA-cleared system for administration of 18F-FDG and 18F-NaF. Intego infuses doses on-demand, providing clinicians with greater flexibility, enhanced workflow, added protection and more accurate, repeatable, patient-specific dosing. Now, through distribution with Comecer, clinicians in Europe and other markets will have easier access to this radiation dose reducing technology.

"Bayer has demonstrated incredible benefits to nuclear medicine facilities with the Intego PET Infusion System," said Emiliano Spagnolo, Director of Sales and Business Development for Comecer. "We are thrilled to take part in extending Intego to customers as part of our portfolio of solutions."

Since its launch in 2008, Bayer HealthCare has continued to enhance the Intego platform, adding software features, expanding compatibility and indications, and significantly reducing the size of the device. Bayer HealthCare will be showcasing the Intego PET Infusion System at the European Congress of Radiology (ECR) in Vienna, Austria, March 7-11, 2013.

About Comecer Group
Comecer Group is a world leader in protection technologies, hot cells manufacturing for nuclear medicine, isolation technology, and nuclear power plant protection/decommissioning. Comecer Group also produces screening software systems and equipment for special applications, designed for large industrial groups and research organizations. It works for hospitals, universities and pharmaceutical companies on tailored projects for the production of isolators for the treatment of toxic and hazardous substances. For more information visit http://www.comecer.com.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.

Our online press service is just a click away: www.press.bayerhealthcare.com

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] PET = positron emission tomography; CT = computer tomography

SOURCE Bayer HealthCare



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES